

BPC-157
Thymosin Alpha 1
Thymosin Beta 4


IMMUNE MODULATING PEPTIDES

William Clearfield D.O.
Suncoast Hotel
NOMA Summer 2019

OBJECTIVES

- *Discuss the fundamentals of the Immune Modulating Peptides.*
- *Discuss the importance of the Cell signaling of Immune Modulating Peptides and its' downstream affects.*
- *Discuss clinical relevance's of BPC-157*


BPC-157



Amino Acids, Proteins and Peptides

- Groups of organic molecules composed of:
 - Amino group (—NH_2)
 - Acidic carboxyl group (—COOH),
 - Organic side chain (R group).

Amino Acid Structure





Amino Acids, Proteins and Peptides

- ***Essential Amino Acids:***
 - **Exogenous** to the body
 - Taken in the form of food or other means. (Intravenous, transdermal or liquid).
 - **Nine Essential A.A.**
 - Histidine, Isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine



Amino Acids, Proteins and Peptides

- ***Non-essential amino acids:***
 - ***Internally generated***
 - alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, proline, serine, and tyrosine



Amino Acids, Proteins and Peptides

- ***Conditional A.A.***
 - Non-essential except in time of stress
 - arginine, cysteine, glutamine, tyrosine, glycine, ornithine, proline, and serine

A background image showing various medical supplies: a large glass vial with a grey cap on the left, a syringe in the center, and several smaller vials and pills (one red and yellow, one red and green) on the right. The scene is set against a light blue background.

*Amino Acids, **Proteins** and Peptides*


- Two or more amino acids linked by a peptide bond in a chain
- Protein chains are > 50 A.A. Combinations
- Enables
 - Growth
 - Repair
 - Gives cells and body, shape
 - Energy Source



Amino Acids, Proteins and **Peptides**

- Structurally similar to proteins
- Contain less than 50 amino acid chains.
- “*Oligopeptides*,” substances with less than twenty, or “*polypeptides*,” consisting of 21-50 amino acids
- Sequence, shape, and type of amino acids involved determine a peptides’ function.

Amino Acids, Proteins and Peptides



amino acids

peptide

protein



Introduction to Peptides

- 7000 known Peptide Sequences
- 500 with sort of therapeutic value
- 60 approved (FDA) as medications.



Skin Repair Peptides

- “A-G-E ing” = 4-letter word
- Built-in senescence=
 - Collagen breaks down.
 - Skin thins and wrinkles =
 - Damaged collagen layer
 - Message “We need more collagen.”
 - Peptides produced, “messengers”
 - Regenerated tissues are incompletely repaired
 - Vicious cycle of breakdown and “disability” of the integumentary system.



Skin Repair Peptides

- XYZ Collagen Skin Repair Cream
 - Peptides
 - The skin “misremembers” its’ repair sequence
 - Accelerates the rate of new collagen restoration.



Peptides Vs. Hormones

1st Peptide isolated: Insulin

Peptides are Tissue Specific

Hormones act globally on body

Mitochondrial Messenger

Intimately involved in the inflammatory process



Peptides vs. Aging


Aging

- Decrease GH,IGF-1
- •Increase cellular Cortisol
- •Sarcopenia (catabolic state)
- •Decreased Insulin sensitivity-**Mitochondrial dysfunction**
- •Decreased cognitive function and memory
- •Decreased immune function
- •Decreased Mitochondrial Biogenesis and efficiency with increased ROS
- •Decreased steroid production (mitochondria)

Peptides

- Immune enhancement
- Sleep
- Memory
- Depression/anxiety
- Improved cognition esp. post TBI
- Antimicrobial, anti-viral, anti-fungal, and antiparasitic agent
- Cellular rejuvenation and restoration
- Pain relief.

Aging and GH/IGF-1





Favorite Peptides

- **Growth Hormone Mimetics**

- GHRH

- Semorelean
- CJC 1295 +/- DAC

- GHRP

- GHRP 2
- GHRP 6
- Ipamorelin
- Hexarelin

- **Immune Modulating Peptides**

- Thymosin Alpha 1 (TA1) (increases TH1)
- Thymosin Beta 4 (T β 4) (increases TH1/decreases TH2))
- BPC-157 (decreases TH2/healing hormone) (oral, SQ, nasal, eye drops) “Homeostasis Peptide.”
- Synergistic with pineal protein Epithalon

- **Rejuvenation/Pain**

- BPC-157, TB4, Epithalon, DSIP, GHRH/GHRP



Favorite Peptides

- **Brain peptides** (memory, depression, anxiety, TBI, brain function, etc.)
 - Cerebrolysin
 - Semax
 - Selank
 - Synergistic with Epithalon, TB4, BPC-157, DSIP
- **Sleep peptides**
 - Epithalon “Homeostasis Peptide”
 - Delta sleep-inducing peptide (DSIP)
 - CJC/Ipamorelin (GHRH/GHRP) (other combo’s)
 - AOD
- **Antimicrobial peptides**
 - LL-37 (effective against Lyme cysts, viruses, fungal, parasites) (synergistic with TA1)




Peptides Act As A Fine Tuning Mechanism

- ❖ Hormones
- ❖ Immune system
- ❖ Sleep
- ❖ Inflammatory cytokines
- ❖ Cell renewal
- ❖ Cancer cell destruction
- ❖ Libido
- ❖ Sexual arousal
- ❖ Weight loss
- ❖ Lean muscle gain
- ❖ Wound healing
- ❖ Brain function
- ❖ Urinary System
- ❖ Reproductive System.



BPC 157

Back to Pavlov



- Isolated pure gastric juice from surgically prepared dogs.
- Calmed the gastrointestinal tract.
 - Treated dyspepsia, gastritis, diarrhea, constipation, heartburn, poor appetite
- Stimulated red blood cell production.
- Determined 12 years after his death to be intrinsic factor. Pavlov's "drug" relieved pernicious anemia.

BPC 157 MECHANISM OF ACTION

...not just protect the brain from damage, but actually help replace and revitalize damaged cells.

promote and restores healthy arteries and veins.

...significantly accelerate bone healing

...protect the liver and promote its regenerative capacity

... protect and promote the health of the intestinal tract

...speed up the repair and regeneration of muscle and cartilage tissue

... promote and accelerate wound repair

... reduce and reverse cardiac (=heart) damage.



BPC 157 MECHANISM OF ACTION

- **BPC-157 promotes new vascular formation.**
- **Stimulates NO production.**
- **Stimulates angiogenic cytokines VEGF, FGF, and TGF- β**
- **Upregulates Anti-Inflammatory Gene Transcription Factor**
- Sikiric P, et al. J Physiol Paris 87: 313–327, 1993.
- L. BRCIC¹, I. BRCIC², M. STARESINIC³, T. NOVINSCAK³, P. SIKIRIC³, S. SEIWERTH¹, MODULATORY EFFECT OF GASTRIC PENTADECAPETIDE BPC 157 ON ANGIOGENESIS IN MUSCLE AND TENDON HEALING ¹Institute of Pathology, University of Zagreb Medical School, Zagreb, Croatia; ². Clinical Department of Pathology and Cytology, University Hospital Center Zagreb, Zagreb, Croatia; ³. Department of Pharmacology, University of Zagreb Medical School, Zagreb, Croatia

BPC 157 MECHANISM OF ACTION


- **Downregulates tumor necrosis factor (TNF)**
- **Influences corneal restoration**
- **Neuroregeneration, esp. from TBI**
- **Upregulates Growth Hormone receptors.**

BPC-157



- ❖ **Leukotriene B4**
- ❖ **Lipid mediators**
 - ❖ Produced during inflammation.
- ❖ **Thromboxane B**
 - ❖ Vasoconstrictor/Hypertensive Agent
- ❖ **Myeloperoxidase**
 - ❖ Proatherogenic enzyme

- **Muscle Tissue Responds >Tendon**
- **Due to vascular affinity of BPC 157**





BPC 157 and Growth Factor Production

- **Insulin derived growth factor**
- **Platelet-derived growth factor**
- **Transforming Growth Factor- Beta**
- **Basic fibroblast growth factor**
- **Vascular endothelial growth factor**
- **Growth Hormone (HGH)**
 - **HGH promotes cell regeneration and proliferation**
 - **HGH growth hormone increases collagen secretion.**



BPC 157 and Ligament Repair

- ***MCL Tear***
 - Promotes microscopic regeneration
 - Functional recovery after injury
 - Stimulates granulation tissue collagen I production
 - Increases fibrin matrix repair mechanism.
 - The recovered ligamentous tissue is thicker and sturdier than before the injury.

BPC 157 AND CORTICOSTEROIDS

- **Corticosteroids long term block nitric oxide collagen synthesis =**
 - **Atrophy of the treated joint, muscle, or tendon.**
- **BPC Blocks Long Term Effects of Corticosteroid Injections**
- **BPC-157 protects endothelium and the formation of scar tissue**



BPC 157 AND THE GI TRACT

- ◆ Revives, repairs and rejuvenates the GI tract.
- ◆ Provides considerably more healing than:
 - ◆ H2-blockers (ranitidine)
 - ◆ Proton pump inhibitors (omeprazole)
 - ◆ Gastric coating agents (sucralfate) ⁽⁸⁾

BPC 157 AND THE GITRACT

❖ Useful adjunct in:

- Inflammatory bowel disease/irritable bowel syndrome
- Ulcerative colitis,
- Leaky gut syndrome
- Diverticulitis
- Gastric reflux
- Crohn's disease,
- Persistent gastric ulcers.

"THE GIRL WITH COLITIS GOES BY."

WRONG, THAT'S THE GIRL WITH KALEIDOSCOPE EYES."

I THOUGHT THE BEAR HAD A THING FOR INFLAMED COLONS.


BPC 157 AND INFLAMMATION

- Prevents and reverses:
 - Mitochondrial damage
 - Inflammatory aspects of rheumatoid arthritis
 - Inflammatory aspects of Lupus and Hashimoto's
 - Heals wounds in corneal epithelium.



BPC 157 AND ANXIETY/DEPRESSION

So I told her this:
Depression and anxiety are teammates
and I'm the opposing team.



- Increases serotonin to a higher degree than SSRI
- Effective against both acute and chronic anxiety.

BPC 157 AND CARDIOVASCULAR S/S (14-17)

- Improves heart failure
- Stabilizes both high and low blood pressure
- Eliminates hyperkalemia (25)
- Prevents and reverses arrhythmias
 - A-Fib, A-V Block, Ventricular tach,
 - Premature atrial contractions
 - Premature ventricular contractions



BPC 157 ADDS DIVERSITY TO YOUR RX. TOOL CHEST

- Reduces and reverses **urinary stress incontinence**
- Protects the liver in the face **of alcohol-induced cirrhosis**
- **Cytoprotective** from NSAID administration, mold, C. difficile, and neurotoxins. ⁽¹⁸⁻²¹⁾

- Prevents **hepatic encephalopathy**
- Interacts with dopamine, serotonin, opioid, and **GABA neurotransmitters**
- Prevents **glutathione depletion**. ⁽²²⁾

- Mitigates neuronal damage, improves early outcomes, and delays mortality in 1st 24 hours **post TBI**. ⁽²³⁻²⁴⁾

BPC 157 ADDS DIVERSITY TO YOUR RX. TOOL CHEST

- **Attenuates:** (25)
 - Behavioral agitation
 - Muscle twitches
 - Restless leg syndrome, leg contractures,
 - Edema
 - Atrophic muscles.
- **Enhances:** (26-28)
 - GH (increases GH receptors)
 - Outperforms acyclovir in the treatment of HSV infection,
 - Normalizes esophageal and pyloric sphincter control.

BPC 157 ADDS DIVERSITY TO YOUR RX. TOOL CHEST

- **Multiple Sclerosis ⁽²⁹⁾**
 - **Decreased nerve damage in the corpus callosum, the laterodorsal thalamus, and anterior horn motor neurons.**
-
- **Wound healing in alkali chemical burns (Topical). ⁽³⁰⁾**
-
- **Corneal abrasions responded 2 pg/ml, 2 ng/ml, 2ug/ml strength. ⁽³¹⁾**
 - **2 drops were administered drops every 8 hours for 40 hours.**

SAFETY OF BPC 157

- No lethal dose (LD1) to kill 1% of the population
 - could be found. ⁽³²⁾
- By contrast, the lethal dose 50 (i.e., the dose needed to kill 50% of a population weighing 75 kg is: ⁽³³⁾
 - 6 liters for water
 - 175 shots of espresso
 - 13 shots of 40% proof alcohol.

LETHAL DOSES OF COMMON CHEMICALS




LD₅₀ stands for 'median lethal dose', and is defined as the amount of a substance required to kill 50% of a test population of animals, expressed in mg per kg of body weight. Human LD₅₀ values are calculated from these tests. For ethical reasons, tests on animals to determine LD₅₀ are being phased out in favour of other methods.

The figures provided below are median lethal doses, and are rough averages for a body weight of 75kg, when the amount specified is taken all at once. Actual figures will vary depending on physical and medical condition.



WATER
6 LITRES



CAFFEINE
118 COFFEES
1 coffee = approx 240ml
(Or 175 shots of espresso)



ALCOHOL
13 SHOTS
Where 1 shot = 45 ml
(40% ABV)



SUMMARY OF POTENTIAL THERAPEUTIC USES (34)

- Lyme disease/HIV (especially in conjunction with TA1)
- Chronic viral or intracellular infections
- CFS/Fibromyalgia
- Autoimmune disease (asthma, lupus, etc..)
- Inflammatory conditions (markers: CRP, C4a, ESR)
- CVD
- Post-surgical
- Diabetes
- Aging
- Allergies/MCAS
- Chemical sensitivity
- GI ulcers/inflammation
- Inflammatory bowel disease
- Leaky Gut
- H-pylori and GERD
- Periodontitis
- Prevent/treat heart arrhythmias

- Mold and toxin exposure
 - Neurodegenerative disease
 - Muscle/tendon/Bone repair
 - Pain Syndromes
 - Eye inflammation and dry eye (with TB4 and stem cell eye drops)
 - Mitochondrial dysfunction
 - Depression anxiety
 - Heart disease/dysfunction
 - Given with stem cells (with TB4)
 - Urinary incontinence
 - Hyper and hypercoagulability
 - HTN and hypotension
 - Adjunct to growth hormone replacement (increases GH receptors)
 - Viral infections
 - Hypothyroidism/thyroid resistance
 - Boosts mitochondrial function
- TBI

BPC 157 DOSING

- Dosing:
 - (Packaged in 2000 mcg/ml 5 ml vials.)
 - Oral Capsules 500 mcg
 -
 - Orally: 500 mcg troche/capsule for GERD.
 - SQ: 800-1000 mcg SQ2x/d x 4-7 days for acute injury. an
 - Joint injection: 1-2 ml. Mix with 1-5 cc of Platelet Rich Plasma.
 - Or
 - 0.15 ml sq daily
 - IV: 2.5 ml (3 mg) with 5 ccs normal saline over 24 minutes for pain. over
 -

REFERENCES

1. Sikiric P, et al. J Physiol Paris 87: 313–327, 1993.
2. L. BRCIC¹, I. BRCIC², M. STARESINIC³, T. NOVINSKAK³, P. SIKIRIC³, S. SEIWERTH¹, MODULATORY EFFECT OF GASTRIC PENTADECAPEPTIDE BPC 157 ON ANGIOGENESIS IN MUSCLE AND TENDON HEALING ¹Institute of Pathology, University of Zagreb Medical School, Zagreb, Croatia; ². Clinical Department of Pathology and Cytology, University Hospital Center Zagreb, Zagreb, Croatia; ³. Department of Pharmacology, University of Zagreb Medical School, Zagreb, Croatia
3. Thromboxane B2, from Wikipedia, https://en.wikipedia.org/wiki/Thromboxane_B2, Accessed June 26, 2019
4. Saltiel, N., Stem Cell Module III, A4M, Course Notes, Dallas, Texas, September 2016, page 27.
5. Cerovecki, Tomislav, et al. "Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat." Journal of Orthopaedic Research 28.9 (2010): 1155-1161.
6. Andrija, et al. "Achilles Detachment in Rat and Stable Gastric Pentadecapeptide BPC 157: Promoted Tendon to Bone Healing and Opposed Corticosteroid Aggravation." Journal of Orthopaedic Research
7. Pevec, Danira, et al. "Impact of pentadecapeptide BPC 15 on muscle healing impaired by systemic corticosteroid application." Medical Science Monitor 16.3 (2010): BR81-BR88.
8. Sikiric P, Seiwert S, Brcic L, Sever M, Klicek R, Radic B, Drmic D, Ilic S, Kolenc D. Revised Robert's cytoprotection and adaptive cytoprotection and stable gastric pentadecapeptide BPC 157. Possible significance and implications for a novel mediator. Current pharmaceutical design. 2010 Apr 1;16(10):1224-34.

REFERENCES

9. Sikiric P, Seiwerth S, Rucman R, Turkovic B, Stancic Rokotov D, Brcic L, Sever M, Klicek R, Radic B, Drmic D, Ilic S. Stable gastric pentadecapeptide BPC 157: novel therapy in the gastrointestinal tract. *Current pharmaceutical design*. 2011 Jun 1;17(16):1612-32.
10. Vuksic T, Zoricic I, Brcic L, Sever M, Klicek R, Radic B, Cesarec V, Berkopic L, Keller N, Blagaic AB, Kokic N. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL14736)
11. Sikiric P, Seiwerth S, Rucman R, Turkovic B, Stancic Rokotov D, Brcic L, Sever M, Klicek R, Radic B, Drmic D, Ilic S. Stable gastric pentadecapeptide BPC 157: novel therapy in the gastrointestinal tract. *Current pharmaceutical design*. 2011 Jun 1;17(16):1612-32.
12. Kralj T, Kokot A, Kasnik K, Drmic D, Zlatar M, Seiwerth S, Sikiric P. Effects of pentadecapeptide BPC 157 on Experimental Rat Model of Dry Eye. *The FASEB Journal*. 2017 Apr 1;31(1 Supplement):993-3.
13. Tohyama Y, Sikiric P, Diksic M. Effects of pentadecapeptide BPC-157 on regional serotonin synthesis in the rat brain: alpha-methyl-L-Tryptophan autoradiographic measurements. *Life Sci* 2004;76(3): 345-57.
14. Lovric-Bencir M, Sikiric P, Hanzevacki JS, et al. Doxorubicin-Congestive Heart Failure-Increased Big Endothelin-1 Plasma Concentration:Reversal by Amlodipine, Losartan, and Gastric Pentadecapeptide BPC157 in Rat and Mouse. *J Pharm Sci* 2004;95:19-26.
15. Jandric I, Vicic H, Balen MJ. Salutary Effect Of Gastric Pentadecapeptide BPC 157 In Two Different Stress Urinary Incontinence Models In Female Rats. *Med Sci Monitor* 2013;19:93-102
16. Balenovic D, Bencic ML, Udovicic M, Simonji K, Hanzevacki JS, Barisic I, Kranjcevic S, Prkacin I, Coric V, Brcic L, Coric M. Inhibition of methyl digoxin-induced arrhythmias by pentadecapeptide BPC 157: a relation with NO-system. *Regulatory peptides*. 2009 Aug 7;156(1-3):83-9.


REFERENCES

17. Sikiric P, Seiwert S, Grabarevic Z, Rucman R, Petek M, Jagic V, et al. Pentadecapeptide BPC 157 positively affects both nonsteroidal anti-inflammatory agent-induced gastrointestinal lesions and adjuvant arthritis in rats. *J Physiol Paris* 1997; 91: 113-22.
18. Sikiric P, Separovic J, Anic T, Buljat G, Mikus D, Seiwert S, et al. The effect of pentadecapeptide BPC 157, H2-blockers, omeprazole and sucralfate on new vessels and new granulation tissue formation. *J Physiol Paris* 1999; 93: 479-85.
19. Sikiric P, Seiwert S, Grabarevic Z, Rucman R, Petek M, Jagic V, et al. Pentadecapeptide BPC 157 positively affects both nonsteroidal anti-inflammatory agent-induced gastrointestinal lesions and adjuvant arthritis in rats. *J Physiol Paris* 1997; 91: 113-22.
20. Blagaic AB, Blagaic V, Romc Z, et al. The influence of gastric pentadecapeptide BPC-157 on acute and chronic ethanol administration in mice. *Eur J Pharmacol* 2004;499(3):285-90.
21. P. Sikiric, S. Seiwert, L. Brcic, M. Sever, R. Klicek, B. Radic, et al., Revised Robert's cytoprotection and adaptive cytoprotection and stable gastric pentadecapeptide BPC 157. Possible significance and implications for a novel mediator, *Curr. Pharm. Des.* 2010;16:1224-1234.
22. Sikiric P, Seiwert S, Rucman R, et al. Toxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC 157. *Curr Pharm*
23. Kliček R, Kolenc D, Šuran J, Drmić D, Brčić L, Aralica G, Sever M, Holjevac J, Radić B, Turudić T, Kokot A. Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon-anastomosis and counteracts cuprizone brain injuries and motor disability. *Journal of physiology and pharmacology.* 2013;64(5):597-612
24. Tudor M, Jandric I, Marovic A, et al. Traumatic brain injury in mice and pentadecapeptide BPC-158 effect. *Regul Pept* 2010;160(1- 3):1-3
25. Stambolija V, Stambolija T, Holjevac J, et al. BPC 157: The counteraction of succinylcholine, hyperkalemia, and
26. arrhythmias. *Euro J Pharm* 2016
27. Chang, CH, Tsai, WC, Hsu, YH, et al. Pentadecapeptide BPC-157 enhances the growth hormone receptor expression in tendon fibroblasts. *Molecules* 2014;19:19066-19077.
28. Turkovic B, Sikiric P, Seiwert S, et al. Gastric Pentadecapeptide BPC 157. a New Stable Peptide in Clinical Phase II for Inflammatory Bowel Disease (Pliva. PL-14736) as Therapy for HSV-1 and HSV-2 Infection. *Gastroenterology* 2003;124(4):A560
29. Stambolija V, Stambolija T, Holjevac J, et al. BPC 157: The counteraction of succinylcholine, hyperkalemia, and arrhythmias. *Euro J Pharm* 2016
30. KLICEK R. ET AL. *JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY* 2013, 64, 5, 597-612
31. SIKIRIC P, ET AL. STABLE GASTRIC PENTADECAPETIDE BPC 157: NOVEL THERAPY IN GASTROINTESTINAL TRACT. *CURR PHARM DES.* 2011; 17: 1612-1632.

REFERENCES

32. Lazic R., et al. Gastric pentadecapeptide BPC-157 promotes corneal epithelial defect healing in rats. COLL ANTHROPOL. 2005 JUN;29(1):321-5.
33. Compound Interest, <https://www.compoundchem.com/2014/07/27/lethaldoses/>, July 2014
34. Huang T., et al. DRUG DESIGN, DEVELOPMENT, AND THERAPY 2015:9 2485–2499
35. Holtorf, K. A4M: International Peptide Society Certification Course. Las Vegas Nevada, December 12-16, 2018
36. "BPC-157 - Holtorfmed.com." <https://www.holtorfmed.com/hq/download/compounding-lab/Peptide-Handouts/bpc-157>

Thymosin Alpha 1



Thymosin Alpha 1-Indications (5)

- Hepatitis B & C
- HIV/AIDS
- Cancer – non-small cell lung (NSCLC), hepatocellular, malignant melanoma
- Chemotherapy adjunct-Reduces hematologic side effects with:
 - Cyclophosphamide
 - 5-fluorouracil (5FU)
 - Dacarbazine
 - Isocyanide
- Chronic inflammatory conditions including autoimmunity
- Cystic fibrosis
- Lyme disease


•

Thymosin Alpha 1-Indications (5)

• **Anything Requiring an Immune Response**

- Steroid-induced apoptosis of thymocytes
- Depressed response to vaccinations; adjunct to the flu vaccine
- Geriatric immune support
- DiGeorge's syndrome
- Sepsis
- Influenza preventive

Thymosin Alpha 1-Mechanism of Action



Improves anti-inflammatory cytokines IL-1 beta, IFN- γ , IL-2, IL-3, IL-6, IL-10. (8-9)

CD3+, CD4+ and CD8+, antioxidant activity by specifically improving intracellular glutathione.

Thymosin Alpha 1-Clinical Pearls

Prolonged mean lifespan by 28% and exhibited a 2.8-fold reduction in all cancers.
(18)

Nonresectable non-small cell lung cancer demonstrated a statistically significant improvement in relapse-free survival ($P=0.04$) when *TA1* was administered for up to 1 year following radiation therapy.

Overall survival ($P=0.009$) correlated with T cell restoration to pretreatment levels. (19)

Thymosin Alpha 1 In Clinical Practice ⁽²⁰⁾

- Women have significantly lower intrinsic TA1 than men ($P < 0.0001$)
- Autoimmune patients are significantly lower in TA1 levels than healthy controls. ($P < 0.0001$)
- Patients on disease-modifying, anti-rheumatic drugs (DMARD) exhibit significantly higher TA1 than autoimmune patients not on DMARDs. The DMARDs crowd remains lower than healthy controls, however.
- TA1 levels are significantly lower in patients with severe infections and cancer.

Thymosin Alpha 1-Side Effects⁽²¹⁾

- **Redness and pain** at the injection site.
- Generalized erythema, transient muscle atrophy, polyarthralgia, and rash.
- A transient increase in ALT, up to twice baseline.
- Current recommendations include continuing therapy unless frank signs of liver failure occur.

Thymosin Alpha 1-Brand Name Drug

Thymalfasin (Brand Name- Zadaxin)

Proprietary thymosin alpha 1 product

Developed by the Shanghai-based SciClone Pharmaceuticals Holding Company.

Approved in 30 countries for hepatitis B and C and as a cancer chemotherapy adjunct. ⁽²²⁾

Indicated for: ⁽²³⁻²⁴⁾

Mono or combination therapy with interferon for the treatment of chronic hepatitis B and C.
Non-small cell lung cancer (NSCLC), hepatocellular carcinoma, AIDS, and malignant melanoma.

Dose:

- 1.6 mg, injected SubQ, 2 times weekly for 6-12 months
- Patients weighing < 40 kg, dosage adjusted to 40 mcg/kg, 2 times weekly.

Thymosin Alpha 1-Dose

Dosage

1.5 mg subcutaneous (SQ) every third day

RX:

- **Viral Infection-2 weeks**
- **HIV/Cancer/Hepatitis/Complicated immune suppression/over-activation-3 mo.**

Has a 2-hour Half-Life

Thymosin Alpha 1 and COVID 19

Genes associated with cytokine signaling and production were upregulated in blood cells from patients with COVID-19

Treatment with T α 1-mitigated cytokine expression inhibited lymphocyte activation in a CD8+ T-cell subset specifically.

Overexpression of IL-6, TNF α , LTA, IL-1 β , and IL-10 and chemokines CCL2 (also known as MCP1) and CXCL6

TA 1down regulates Il-6, TNF a, IL-1 B and upregulates IL-1o

Claudia Matteucci, Antonella Minutolo, Emanuela Balestrieri, Vita Petrone, Marialaura Fanelli, Vincenzo Malagnino, Marco Ianetta, Alessandro Giovinazzo, Filippo Barreca, Silvia Di Cesare, Patrizia De Marco, Martino Tony Miele, Nicola Toschi, Antonio Mastino, Paola Sinibaldi Vallebona, Sergio Bernardini, Paola Rogliani, Loredana Sarmati, Massimo Andreoni, Sandro Grelli, Enrico Garaci, Thymosin Alpha 1 Mitigates Cytokine Storm in Blood Cells From Coronavirus Disease 2019 Patients, Open Forum Infectious Diseases, Volume 8, Issue 1, January 2021, ofaa588, <https://doi.org/10.1093/ofid/ofaa588>

No significant association between thymosin α 1 treatment and mortality.

Liu, Tao et al. "Thymosin a1 use is not associated with reduced COVID-19 mortality." The American journal of emergency medicine, S0735-6757(21)00329-6. 19 Apr. 2021, doi:10.1016/j.ajem.2021.04.043

REFERENCES

1. **Barkley, T. "The Thymus Gland"**
https://www.innerbody.com/image_endoov/lymp04-new.html,
2. **"Introduction To Peptide Therapy - Nahypothyroidism.org."** Insert Name of Site in Italics.
N.p., n.d. Web. 04 Jul. 2019
<https://www.nahypothyroidism.org/wp-content/themes/nah-2015/lecture-series/files>.
Consolini R, Legitimo A, Calleri A, et al. Distribution of age-related thymulin titers in normal subjects through the course of life. Clin Exp Immunol 2000; 121:444-447
3. **Gui J, Mustachio LM, Su DM, et al. Thymus Size and Age-related Thymic Involution: Early Programming, Sexual Dimorphism, Progenitors, and Stroma. Aging Dis 2012;3(3):280-90**
4. **Holtorf, K. A4M: International Peptide Society Certification Course. Las Vegas Nevada, December 12-16, 2018**
5. **"What Is Thymosin Alpha 1? - Blog.transformyouaz.com."** Insert Name of Site in Italics.
N.p., n.d. Web. 04 Jul. 2019
<http://blog.transformyouaz.com/blog/what-is-thymosin-alpha-1>.
6. **I, J., C.H. Liu, and F.S. Wang, *Thymosin alpha 1: Biological activities, applications, and genetic engineering production*. Peptides, 2010. 31(11): p. 2151-2158.**
7. **Garaco E, Pica F, Serafino A, et al. Thymosin alpha-1 and cancer: action on immune effector and tumor target cells. Ann NY Acad Sci. 2012;1269:26-33.**
8. **Romani L, Moretti S, Fallarino F, et al. Jack of all trades: thymosin alpha-1 and its pleiotropy. Ann NY Acad Sci. 2012;1269:1-6.**


REFERENCES

9. Romani L, Bistoni F, Perruccio K, et al. Thymosin alpha 1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance. *Blood*. 2006;108(7):2265-74.
10. Tuthill, C., King, R., Thymosin Alpha 1 -A Peptide Immune Modulator with a Broad Range of Applications, *Semantic Scholar*, 2013 DOI:104172/2161-1459 1000133
11. Holtor, K., Smith, K.O. Introduction To Peptide Therapy - *Nahypothyroidism.org*." N.p., n.d. Web. 04 Jul. 2019
<https://www.nahypothyroidism.org/wp-content/themes/nah-2015/lecture-series/files>.
12. Beermann C, Wunderli-Allenspach H, et al. Lipoproteins from *Borrelia burgdorferi* applied in liposomes and presented by dendritic cells induce CD8(+) T-lymphocytes in vitro. *Cell Immunol* 2000;201(2):124-31
13. Results of Palatin Technologies' PT-141 phase 2b study in men with erectile dysfunction, May 10, 2004. www.palatin.com.
14. Wessells H, Gralnek D, Dorr R, Hruby VJ, Hadley ME, Levine N. Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. *Urology*. 2000 Oct 31;56(4):641-6. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation
15. Beermann C, Wunderli-Allenspach H, et al. Lipoproteins from *Borrelia burgdorferi* applied in liposomes and presented by dendritic cells induce CD8(+) T-lymphocytes in vitro. *Cell Immunol* 2000;201(2):124-31
16. Rui L, Yu N, Hong L, et al. Extending the time window of mammalian heart regeneration by thymosin beta 4. *Journal of cellular and molecular medicine*. 2014 Dec 1;18(12):2417-24.

REFERENCES


17. .G. and V.K. Khavinson, Natural and synthetic thymic peptides as therapeutics for immune dysfunction. *International Journal of Immunopharmacology*, 1997. 19(9-10): p. 501-505
18. Schulof, R.S. A randomized trial to evaluate the immunorestorative properties of synthetic thymosin-alpha 1 in patients with lung cancer. *J. Biol. Response Modif.*, 1985. 4: p. 12.
19. Pica E, Chimenti S, Gaziano, R, et al. Serum thymosin alpha 1 levels in patients with chronic inflammatory autoimmune disease. *British Soc immunology: Clin & Experiment Immunology* 2016;186;39-45 TA1
20. International Peptide Society, *Thymosin Alpha 1 Monograph*, 2018, Cincinnati, OH, 2018; 8
21. Wu X, Jia J, You H. Thymosin alpha 1 treatment in chronic hepatitis B. *Expert Opin Biol Ther.* 2015;15 Suppl 1:S129-32.
22. Billich A. Thymosin alpha 21. *SciClone Pharmaceuticals. Curr Opin Investig Drugs.* 2002;3(5):698-707.
23. HE C, Peng W, Li C, et al. Thymalfasin, a promising adjuvant therapy in small hepatocellular carcinoma after liver resection. *Medicine (Baltimore).* 2017;96(16):e6606.

Thymosin Beta 4




MUSCLE FUNCTIONS

- *Muscles contract and relax by the sliding of one protein, myosin, over the other protein, actin, in a series of repetitive events.* ⁽¹⁾
-
- *Myosin is a thick motor protein, and actin is the thinner, scaffolding filament.*
-



THYMOSIN BETA 4

- 43 amino acid peptide
- Found in almost every cell in the body,
- Upregulates actin, responsible for muscle contraction
- Stimulates the formation of healing cells
- Improves cell migration to a site of injury. ⁽³⁾
- Anti-inflammatory, antiviral
- Cardio and neuroprotective.



a)

Thymosin Beta 4 and Infectious Diseases

b)

Acute

- Influenza
- URI
- Ebola
- Zika viruses.

Chronic

- HIV
- Lyme disease
- Malaria
- Herxheimer reactions ⁽⁴⁾
- Combine w Cipro for Improved response to Pseudomonas aeruginosa in the eye ⁽⁶⁾

•

a)

Thymosin Beta 4 and Chronic Inflammatory Diseases (5)

- MI
- Pre and post-op surgical preparation and recovery
- Remyelinating nerve tissue damaged:
Alzheimer's
 - MS
 - Peripheral neuropathy.

b)

- Hepatoprotective in alcohol and LPS liver injury
- Prevents ethanol and LPS mediated increases liver enzymes
- Prevents jumps in LPS and alcohol-induced oxidative stress.
- Decreases reactive oxygen species and lipid peroxidation
- Increases antioxidants
 - Glutathione
 - Manganese-dependent superoxide dismutase.
- Prevents excess proinflammatory cytokine formation and liver fibrosis. (7)

a)

Thymosin Beta 4 and Chronic Inflammatory Diseases (5)

Wound repair.

Anti-inflammatory

angiogenesis

Increases collagen deposition,

Cytoprotective. (8)

Angiogenesis


Antifibrosis

Reduces infarct volume

Preserves cardiac function

Improves cardiac wound repair.

b)




a)

Thymosin Beta 4 in Clinical Practice ⁽⁵⁾

- ✓ Soft Tissue Repair—tendons, ligaments, muscle, sport, and athletic injuries.
- ✓ Pressure or venous stasis ulcers.
- ✓ Conditions requiring immune response modulation
- ✓ Brain issues if autoimmunity suspected
- ✓ Ischemic stroke
- ✓ Spinal cord injuries
- ✓ TBI / concussion/MS (in conjunction with BPC-157)
- ✓ Dry eye disorders

b)

(5)




a)

Thymosin Beta 4 in Clinical Practice ⁽⁵⁾

b)

- Phase II clinical trials –RegeneRx
- Corneal injuries
- Phase 3 US trial for Epidermolysis bullosa
- Lung inflammation –pulmonary fibrosis
- May improve hair growth
- Non-Alcoholic Fatty Liver
 - Inhibits oxidative stress
 - Decreases proinflammatory cytokines
 - Decreases hepatic fibrosis
- Cardioprotective
- Reduces endotoxemia-use in sepsis
- Reduces mortality



a)

b)


Thymosin Beta 4 and Multiple Sclerosis

- Demyelinating disease
- Affects brain and spinal cord
- T cells penetrate BBB
- Initiate myelin attack
- Autoreactive lymphocytes
- Treatment options limited

- M.S. presents w infectious etiology. ⁽¹¹⁾
- Epstein-Barr virus (EBV) explains the key features of MS epidemiology. ⁽¹²⁾
- 10-20 fold increase in incidence of M.S w EBV infections, ⁽¹³⁾

Thymosin Beta 4 and Multiple Sclerosis

- **MS + TB 4 =**
 - Improved functional outcomes.
 - Neuroprotective and anti-inflammatory
 - Neuroregenerative
 - Neurons, oligodendrocytes, microglia.
 - Restores myelin,
 - Synaptogenesis,
 - Enables axon growth.



Demyelination by MS.
The CD68 colored tissue shows several macrophages in the area of the lesion

a)

b)

Thymosin Beta 4, Thymosin Alpha 1 and Multiple Sclerosis

TB 4

- Targets multiple cells
- Neurorestorative:
 - Reduces Axonal Damage, Apoptosis
 - Remyelinating
 - Rewrapping of Axons
- Neuroprotective
- Anti-inflammatory

TB 1

- Pleiotropic
- Adaptogenic
- Induces Regulatory B Cells
- Reduces Proinflammatory B Cells
- Anti-Inflammatory
- Anti-viral

a)

Thymosin Beta 4

b)

•Dose:

-
- Thymosin Beta 4: 3000 mcg/ml -> 300-1000 mcg subcutaneous daily.
- Treat cycle is three months on, one month off.
- May use concurrently with Thymosin Alpha 1 and BPC-157

PUTTING IT ALL TOGETHER

a)

b)

Immunoregulation *TA1*




Neuro Repair *TB 4*



GI/Leaky Gut *BPC 157*



Systemic Repair *HGH*
Secretagogues



Thymosin Beta 4 References

- a) 1. <https://study.com/academy/lesson/muscle-contraction-actin-and-myocin-bonding.html>, Accessed July 4, 2019
2. Doherty GJ, McMahon HT (2008). "Mediation, modulation, and consequences of membrane-cytoskeleton interactions." *Annual Review of Biophysics*. **37** (1): 65–95. [doi:10.1146/annurev.biophys.37.032807.125912](https://doi.org/10.1146/annurev.biophys.37.032807.125912). [PMID 18573073](https://pubmed.ncbi.nlm.nih.gov/18573073/)
3. Sanders MC, Goldstein AL, Wang Y. Thymosin B4 (Fx peptide) is a potent regulator of actin polymerization in living cells. *Proc Natl Acad Sci USA*. 1992;89:4678-4682.
4. Carion TW, Kracht DJ, Strand E, et al. Thymosin beta-4 and Ciprofloxacin Adjunctive Therapy Improves Pseudomonas Aeruginosa Induced Keratitis. 5th International Symposium in health and disease; Thymosins, Nov 15-17, 2017
5. Philp D, Kleinman HK. Animal studies with thymosin β 4, a multifunctional tissue repair, and regeneration peptide. *Annals of the New York Academy of Sciences*. 2010 May 1;1194(1):81-6.
6. Carion TW, Kracht DJ, Strand E, et al. Thymosin beta-4 and Ciprofloxacin Adjunctive Therapy Improves Pseudomonas Aeruginosa Induced Keratitis. 5th International Symposium in health and Disease; Thymosins, Nov 15-17, 2017
7. Shahi R, Gordillo KR, Cheng Y, et al. The Hepatoprotective Role of Thymosin Beta 4 in alcoholic Liver Injury and Fibrosis. 5th International Symposium in health and Disease; Thymosins, Nov 15-17, 2017
8. Sanders MC, Goldstein AL, Wang Y. Thymosin B4 (Fx peptide) is a potent regulator of actin polymerization in living cells. *Proc Natl Acad Sci USA*. 1992;89:4678-4682.
- b)

Thymosin Beta 4 References

- a)
9. Kleinman HK, Sosne G. Thymosin B4 promotes dermal healing. *Vitam Horm.* 2016;102:251-75.
10. Yarmola EG, Kilmenko ES, Fujita G, et al. Thymosin beta4: actin regulation and more. *Ann NY Acad Sci.* 2007;1112:76-85.
11. Ascherio, A., Munger, K., Environmental Risk Factors for Multiple Sclerosis. Part I: The Role of Infection. *Ann Neuro.* 2007, Apr; 61 (4): 288-299
12. IBID
13. IBID
14. Severa, M., et. Al; Multiple Sclerosis and Related Disorders 27 (2019) 52-60
15. Severa, M., et. Al; Multiple Sclerosis and Related Disorders 27 (2019) 52-60
- b)
- 

	Class	Pain	Immunity	Inflammation	Libido	Anti-Aging	Weight Loss	Cognitive	Antioxidant	Sleep	Dose	Conditions
Thymosin Alpha 1	TH 1 Stimulation	+	+++	++		++		+	++		50-300 mcg/d	Immune boost; CA, Infections
Thymosin Beta 4	TH1/TH2 Balance	++	+++	+++		++		++	++	+	50-300 mcg/d	Immune modulation, CA, Neurorejuvenation, muscle pain
BPC 157	Anti-inflammatory	+++	+++	+++		+++	+	+	+++	+	Oral 500 mg 1-4/d/50-200 2/d	Wound healing, orthopedic repair, GI Healing, rejuvenation
Epithalim	Pineal Peptide										50-150mg/d	Anti-biofilm, infections, Lyme, anti-bacterial, antibiotic, antiviral, immunomodulation

Peptide Summary

	Class	Pain	Immunity	Inflammation	Libido	Anti-Aging	Weight Loss	Cognitive	Antioxidant	Sleep	Dose	Conditions
PT-141	MSH Analog				++		+				1-2 mg 2x/d	Libido, Weight Loss, Tanning
GHRH/GHRP	HGH Mimic		+	+		+	+	+		++	160-400 mg @ hs	Healing, Body Fat, Rejuvenation
Semax	Nootropic	+	+	++	+	+++		+++	++	+	100-300 mg/d	Cognitive Dysfunction, Memory,
Selank	Nootropic		+	+		+		++	+	++	100-300 mg/d	Dementia, Stroke, TBI
CJC/Ipamorelin	GHRP/GHRH		+	+		++	+	+		++	150-300 mg/d	GH Stimulation

The background of the slide is a microscopic image showing various biological structures, including what appears to be a large, multi-lobed cell or organism in shades of blue and green. A prominent red banner is located in the top right corner, containing the text 'Thank You' in white. A large, semi-transparent white circle is positioned on the left side of the slide, containing the event details.

Thank You

**To Learn More Come to the
American Osteopathic Society of
Rheumatic Diseases
OMED 2021,
October 22-24, 2021
Phoenix, Arizona**

**Weekly Tuesday Night Webinar
8 PM Eastern, 5 PM Pacific**

<https://us02web.zoom.us/j/88326129245>